Antibiotic Treatment for UTI with Early Kidney Involvement

First-Line Treatment Options

The European Urology guideline recommends a 7-day course of intravenous third-generation cephalosporin, or a combination of amoxicillin plus an aminoglycoside or second-generation cephalosporin plus an aminoglycoside for patients with UTI and early kidney involvement 1
For patients with systemic symptoms indicating early kidney involvement, the Journal of Microbiology, Immunology and Infection suggests using intravenous third-generation cephalosporin or second-generation cephalosporin plus an aminoglycoside as empirical treatments 2
Fluoroquinolones should only be used if local resistance rates are <10% and the entire treatment can be given orally, the patient doesn't require hospitalization, or the patient has anaphylaxis to β-lactam antimicrobials, according to the European Urology guideline 1

The Clinical Infectious Diseases guideline recommends a 7-day course for patients with prompt symptom resolution, and extending to 10-14 days for patients with delayed response 4
A 5-day regimen of 750mg once daily levofloxacin may be considered for patients who are not severely ill, as suggested by the Clinical Infectious Diseases guideline 4

The European Urology guideline states that the microbial spectrum for UTIs with kidney involvement is broader than uncomplicated UTIs and includes E. coli, Proteus spp., Klebsiella spp., Pseudomonas spp., Serratia spp., and Enterococcus spp. 1
The Clinical Infectious Diseases guideline recommends obtaining urine culture before initiating antibiotics due to the wide spectrum of potential pathogens and increased likelihood of resistance 4
If a urinary catheter has been in place for ≥2 weeks, it should be replaced before starting antibiotics to improve treatment efficacy, as suggested by the Clinical Infectious Diseases guideline 4

For UTIs caused by carbapenem-resistant Enterobacterales (CRE), the Journal of Microbiology, Immunology and Infection suggests considering ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, or plazomicin 2

The European Urology guideline warns against using fluoroquinolones empirically in areas with high resistance (>10%) 1
The Clinical Infectious Diseases guideline emphasizes the importance of obtaining cultures before starting antibiotics and not using too short a treatment course for patients with delayed response 4